Medical Affairs, once considered a support function, now has a seat at the table as one of the major pillars of biopharmaceutical organizations. So now what? Our new Medical Affairs series, which will unfold over the next several months, will explore what’s next and provide insights and best practices for “Next Gen” Medical Affairs.
In this first episode of the series, Suma Ramadas, Senior Managing Director in the Scientific and Medical Affairs Advisory Group for Syneos Health Consulting, sets the foundation for discussion around the Medical Affairs function, how it can continue to communicate its worth, work effectively with Clinical and Commercial functions, and develop efficient processes – beginning earlier in development – that propel commercial planning and drive greater asset value.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].